Pfizer Inc. (NYSE:PFE) Shares Acquired by Valley Wealth Managers Inc.

Valley Wealth Managers Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 678,742 shares of the biopharmaceutical company’s stock after purchasing an additional 28,933 shares during the period. Valley Wealth Managers Inc.’s holdings in Pfizer were worth $19,643,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Pfizer during the first quarter valued at $315,000. Dorsey & Whitney Trust CO LLC boosted its holdings in Pfizer by 16.0% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 72,467 shares of the biopharmaceutical company’s stock valued at $2,011,000 after purchasing an additional 9,989 shares during the last quarter. Forum Financial Management LP boosted its holdings in Pfizer by 1.8% in the first quarter. Forum Financial Management LP now owns 57,342 shares of the biopharmaceutical company’s stock valued at $1,591,000 after purchasing an additional 1,033 shares during the last quarter. M&G Plc purchased a new stake in Pfizer in the first quarter valued at $19,885,000. Finally, Poehling Capital Management INC. boosted its holdings in Pfizer by 9.3% in the first quarter. Poehling Capital Management INC. now owns 54,416 shares of the biopharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 4,609 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

PFE stock traded down $1.25 during mid-day trading on Friday, reaching $24.77. The company’s stock had a trading volume of 9,747,602 shares, compared to its average volume of 37,684,727. The stock has a market cap of $140.37 billion, a PE ratio of 33.37, a P/E/G ratio of 0.85 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.52 and a fifty-two week high of $31.54. The company’s 50 day moving average is $28.71 and its two-hundred day moving average is $28.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.17) EPS. Equities research analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.78%. Pfizer’s dividend payout ratio is currently 227.03%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup assumed coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday. They set an “underperform” rating and a $25.00 target price on the stock. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $32.92.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.